Abstract
Current therapies for neuropathic pain are often inadequate and several promising preclinical drugs have failed in clinical trials. This may stem from an overreliance on reflex-based outcomes, which do not accurately reflect the spontaneous or non-evoked pain (NEP) characteristic of neuropathic pain. To bridge this gap, we evaluated the preclinical efficacy of standard analgesics in relieving NEP associated with neuropathic pain, thereby providing valuable insights that could optimize preclinical testing. A comprehensive search was performed in PubMed, Scopus, and Web of Science (July 2023). A random-effects model evaluated the effect of the intervention, with subgroup analyses exploring variability sources. Of the 91 included studies, 65 were eligible for meta-analysis, yielding 196 drug evaluations. Most evaluations involved traumatic nerve injury (91%) in male animals, although fewer were nontraumatic neuropathies (6%) or spinal cord injuries (4%). Standard pharmacotherapy for neuropathic pain relieved NEP with efficacy patterns closely matching clinical results. Tricyclic antidepressants and selective serotonin reuptake inhibitors showed the highest efficacy, followed by gabapentinoids and strong opioids, whereas nonsteroidal anti-inflammatory drugs and mild opioids had no significant effect. Next, we confirmed that all the NEP-related behaviors were significantly alleviated by standard analgesics, validating that they are indeed pain associated. Moreover, drug efficacy was greater in traumatic nerve injury models compared with nontraumatic neuropathy models. In conclusion, standard analgesics demonstrated robust preclinical efficacy in alleviating NEP, mirroring their clinical performance. These findings underscore the importance of incorporating assessments of spontaneous pain into classical tests in preclinical studies to enhance the clinical translation of investigational analgesics.